Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

AbbVie

Status and phase: Completed; Phase 1

Conditions: Progressive Supranuclear Palsy (PSP)

Treatments: Drug: ABBV-8E12

Study type: Interventional

Funder types: Industry

Identifiers

NCT03413319

M16-948

Details and patient eligibility

About

The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

Enrollment: 3 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject completed Study C2N-8E12-WW-104 (NCT02494024)
• Subject was not eligible to enroll in Study M15-562 (NCT02985879)

Exclusion criteria

• Subject weighs less than 35 kg at screening
• Subject has any contraindication or inability to tolerate brain MRI
• Subject has any significant change in his/her medical condition that could interfere with the subject's participation in the study, could place the subject at increased risk, or could confound interpretation of study results

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

3 participants in 1 patient group

ABBV-8E12

Experimental group

Description:

ABBV-8E12 administered by intravenous (IV) infusion.

Treatment:

Drug: ABBV-8E12